New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
2104 Annual Clinical Meeting of ACOG is being held in Chicago on April 26-30.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 18, 2015
08:11 EDTRHHBY, SNY, PFE, MRKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 XALKORI trial shows 'positive' results
Subscribe for More Information
07:43 EDTABBVJefferies to hold a conference
Subscribe for More Information
07:02 EDTPFEMerck KGaA, Pfizer win FDA breakthrough therapy designation for Avelumab
Subscribe for More Information
07:01 EDTMRKThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
06:09 EDTPFEValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information
06:03 EDTBAYRYBayer says not looking to sell crop chemicals business, Reuters reports
Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link
November 17, 2015
15:02 EDTATHNathenahealth announced new services agreement with TeamPraxis
athenahealth and TeamPraxis, a physician service organization in Hawaii, announced a new services agreement which enables TeamPraxis to access and use the athenaNet platform to implement and support the athenaOne suite of services and athenaCommunicator Enterprise population health service.
11:23 EDTATHNBarclays says sell athenahealth as new customers get harder to find
Barclays downgraded athenahealth (ATHN) to Underweight, the firm's equivalent of a Sell rating, in a note to investors today. The company's prospects in the ambulatory care market look weak and its growth rate appears to be unsustainable, the firm contended. athenahealth provides cloud-based services and mobile applications to medical groups WHAT'S NEW: After analyzing the ambulatory enterprise market, Barclays analyst Eric Percher reported that only 12 of the 100 largest names on the list are potential targets for athenahealth. Additionally, those dozen groups are much smaller than the ones with which athenahealth made deals in 2014 and earlier this year, wrote Percher. Given his findings, the analyst expects athenahealth's revenue growth to decline going forward. In order to accelerate its growth, athenahealth needs large contract wins and those are unlikely to occur in the near-term, predicted the analyst, who downgraded the stock to Underweight from Equal Weight and lowered his price target on the name to $110 from $140. WHAT'S NOTABLE: JPMorgan analyst Michael Newshel assumed lead coverage of athenahealth today with an Overweight rating and $170 price target. In his note this morning on the space, Newshel said his firm's latest hospital CIO survey indicates there will be no slowdown in HIT investments despite the electronic health records adoption cycle maturing. PRICE ACTION: In morning trading, athenahealth fell 6.6% to $152.22.
10:09 EDTABBVAbbVie management to meet with Jefferies
Subscribe for More Information
10:02 EDTSYKHigh option volume stocks
Subscribe for More Information
10:00 EDTATHNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded on valuation at KeyBanc... BHP Billiton (BHP) downgraded to Neutral from Buy at Clarksons Platou... Chesapeake (CHK) downgraded to Neutral from Buy at Sterne Agee CRT... ChipMOS (IMOS) downgraded to Equal Weight from Overweight at Morgan Stanley... Clovis (CLVS) downgraded to Neutral from Conviction Buy at Goldman... Cooper Companies (COO) downgraded to Market Perform from Outperform at Wells Fargo... Five Below (FIVE) downgraded to Neutral from Buy at Sterne Agee CRT... Grainger (GWW) downgraded to Underweight from Neutral at Atlantic Equities... Hess Corp. (HES) downgraded to Perform from Outperform at Oppenheimer... J Sainsbury (JSAIY) downgraded to Neutral from Buy at Citi... Kindred Biosciences (KIN) downgraded to Market Perform from Outperform at BMO Capital... Leju (LEJU) downgraded to Neutral from Buy at BofA/Merrill... Lombard Medical (EVAR) downgraded to Equal Weight from Overweight at Barclays... Osiris (OSIR) downgraded to Sell from Hold at Brean Capital... Polaris Industries (PII) downgraded on anemic ORV growth at Wedbush... SQM (SQM) downgraded to Hold from Buy at HSBC... Southwestern Energy (SWN) downgraded to Underperform from Neutral at Sterne Agee CRT... Starwood (HOT) downgraded to Outperform from Buy at CLSA... Urban Outfitters (URBN) downgraded to Hold from Buy at Cantor... WM Morrison (MRWSY) downgraded to Sell from Neutral at Citi... adidas (ADDDY) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underweight from Equal Weight at Barclays.
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
08:05 EDTABBVInfinity reaches target enrollment in Phase 3 study of duvelisib
Subscribe for More Information
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:26 EDTATHNThe Advisory Board initiated with an Overweight at JPMorgan
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
05:43 EDTATHNathenahealth downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Eric Percher downgraded athenahealth to Underweight saying the company's physician and revenue growth will decline moving forward. An analysis of the ambulatory enterprise market indicates that potential athenahealth targets among the 100 largest health systems number only 12, Percher tells investors in a research note. Big enterprise wins are needed to drive growth but are "few and far between," the analyst contends. He cut his price target for athenahealth to $110 from $140. The provider of cloud-based services for medical groups and health systems closed yesterday up $1.77 to $162.98.
05:22 EDTPFEStocks with implied volatility movement; P PFE
Stocks with implied volatility movement; Pandora (P) 104, Pfizer (PFE) 29 according to iVolatility.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use